Low dosage of apatinib monotherapy as rescue treatment in advanced lung squamous cell carcinoma
- 43 Downloads
Platinum-based doublet chemotherapy and radiotherapy are the standard treatment option in advanced squamous cell carcinoma patients. However, few agents could be selected for subsequent post-second-line treatment. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase, apatinib had been proved in advanced gastric cancer. Here, we showed its efficacy and safety in lung squamous cell carcinoma.
In this retrospective study, 13 advanced lung squamous cell carcinoma patients were enrolled. They received doublet chemotherapy or docetaxel as the first-line treatment. After disease progressed, all patients were administrated apatinib monotherapy (250–425 mg/day) for second-line or fourth-line therapy.
After apatinib monotherapy, two patients achieved partial response, four patients achieved stable disease, and seven patients achieved progression disease. The medium PFS was 3.1 months. The median OS had not yet been reached. The objective remission rate was 15.4% (2/13). The total disease control rate was 46.2% (6/13). The main advert effects were vomiting and hypertension.
Apatinib might be an option as rescue treatment in advanced lung squamous cell carcinoma.
KeywordsSquamous cell carcinoma VEGFR-2 Apatinib
This study was supported by Jiangsu Province Special Program of Medical Science (BE2016672), Program of Key Talents of Medical Science in Jiangsu Province (QNRC2016745), Clinical Key Speciality Project of China, Clinical Medicine Center of Suzhou (No. SZZX201502), Suzhou Key Laboratory for Respiratory Medicine (No. SZS201617).
Compliance with ethical standards
Conflict of interest
No conflict of interest.
- 1.Gridelli C, de Marinis F, Cappuzzo F et al (2014) Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 15:173–181CrossRefGoogle Scholar
- 6.Garon EB, Ciuleanu TE, Arrieta O et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384:665–673CrossRefGoogle Scholar